NK cell companies agree they differ, but not on what features matter most
BioCentury – View full story (behind a paywall)
Up and down the ladder: The latest comings and goings
StatNews – View full story (behind a paywall)
Optimized Affinity CD38 CAR-NK Therapy Shows Early Promise in Multiple Myeloma
BioSpace – View full story
Progress in the Development of CAR NK-Cell Therapies
Pharmaceutical Technology – View full story
Intellia and ONK collaborate on cancer candidates
Endpoints News – View full story
Intellia-ONK ink up to $920 million pact for 5 CRISPR-edited cancer cell therapies
Fierce Biotech – View full story
Intellia and ONK Therapeutics enter collaboration
The Pharma Letter – View full story
Intellia follows CRISPR peers with deal to explore ‘natural killer’ cell therapy
BioPharma Dive – View full story
